Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Eganelisib,一种首创的PI3Kγ抑制剂,用于治疗晚期实体瘤患者:1/1b期MARIO-1试验结果
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-3313
Hong, David S; Postow, Michael; Chmielowski, Bartosz; Sullivan, Ryan; Patnaik, Amita; Cohen, Ezra E W; Shapiro, Geoffrey; Steuer, Conor; Gutierrez, Martin; Yeckes-Rodin, Heather; Ilaria, Robert; O'Connell, Brenda; Peng, Joanna; Peng, Guangbin; Zizlsperger, Nora; Tolcher, Anthony; Wolchok, Jedd D